Keros Therapeutics
IPO News: Filed S-1/A: Keros Therapeutics Launches 5mm Share IPO

Keros Therapeutics

NASDAQ:  KROS

Initial Filing Date:  03/16/20

Launch Date:  04/01/20

Price Range:  $14.00 - $16.00

Shares Offered (Pre-Shoe | mm):  5.0

Primary Shares (mm):  5.0

Secondary Shares (mm):  0.0

Amount Offered (@ Midpoint)(mm):  $75.0

% Secondary:  0.0%

Shares Outstanding (mm):  18.2

Market Value at Midpoint (mm):  $272.8

Offering as % of Market Value:  27.5%

Bookrunners:  Jefferies | SVB Leerink | Piper Sandler

Co-Manager:  H.C. Wainwright

Major Holders:  Pontifax Venture Capital | Arkin Bio Ventures LP | Foresite Capital Management | Partners Innovation Fund | OrbiMed

Description:  Keros is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need.

Note:  Emerging Growth Company

 

Reference Link:  S-1/A